ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Periodontal Treatment on Systemic Inflammation and for Prevention of Exacerbations in Patients With COPD (Expertention)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03279718
Recruitment Status : Recruiting
First Posted : September 12, 2017
Last Update Posted : May 4, 2018
Sponsor:
Information provided by (Responsible Party):
Michael Kreuter, Heidelberg University

Brief Summary:

Current data are showing a potential link between inflammatory biomarkers in chronic periodontitis and COPD. However the impact of periodontal treatment on systemic inflammation as measured by biomarkers and time to occurrence of acute exacerbations (AECOPD) remains an important but unresolved issue. This pilot study will provide information on effects of periodontal treatment on systemic inflammation and the course of COPD including acute exacerbation.

40 patients with chronic periodontitis and COPD will be included in this study. First baseline information (age, gender, lifestyle, smoking history, medical history, medication, frequency of exacerbation, dental treatments) are recorded. Then patient's health status is assessed using the COPD Assessment Test (CAT) and a comprehensive lung function testing (bodyplethysmograph) is conducted to assess lung functional severity of COPD. Blood samples are taken for analysis of various inflammatory biomarkers and saliva and sputum samples are collected for analysis of microbiome.

Afterwards experienced dentists will conduct oral health examination and record the periodontal conditions of every patient. Samples of gingival crevicular fluid for determining Matrix metallopeptidase 8 (MMP8), Interleukin 1 beta (IL-1beta) and Interleukin 6 (IL-69 levels and for microbiome analysis will be taken. After randomization to one of the two study groups (intervention group: periodontal treatment / control group: no periodontal treatment) all patients get comprehensive oral hygiene instructions, irrespective of their periodontal status . Patients of the control group receive no further planned dental intervention. For patients of the experimental group, who need periodontal treatment due to the presence of periodontal pocket depth of ≥ 4 mm an appropriate care plan will be determined and supra- and subgingival scaling and root planing will be performed.

During a 3, 6 and 12 months follow-up patient's current health condition will be assessed using the CAT. Additionally lung function tests (bodyplethysmograph) will be performed and clinical periodontal parameters are re-evaluated. To detect and assess COPD exacerbations in this trial, patients will complete a daily diary during the whole follow-up period which will be provided to the clinical researcher at each study visit. Furthermore the cough and sputum assessment questionnaire (CASA-Q)) will be used at each telephone call and at each visit in the pulmonary center. After 6 and 12 months blood, sputum, saliva and gingival crevicular fluid will be taken additionally. To understand the microbial ecology mechanisms linking periodontitis to COPD combined analysis of oral cavity microbiome (GCF) and lung microbiome (sputum) will be conducted. The biomarkers high sensitive C-reactive Protein (hsCRP), MMP8, IL-1beta und IL-6 will be determined in blood and in gingival crevicular fluid, respectively.


Condition or disease Intervention/treatment Phase
COPD Exacerbation, Periodontal Health Procedure: Periodontal Treatment Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Exploring Efficacy of Periodontal Treatment on Systemic Inflammation and for Prevention of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Pilot Study
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : October 1, 2019
Estimated Study Completion Date : March 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dental Health

Arm Intervention/treatment
Experimental: periodontal treatment Procedure: Periodontal Treatment
Scaling and root planing

No Intervention: only oral hygiene instruction, no treatment



Primary Outcome Measures :
  1. Change in blood serum inflammatory biomarker hsCRP [ Time Frame: after 6 months and after 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

COPD functional class B to D (moderate to very severe) according to the Global Initiative For Chronic Obstructive Lung Disease (GOLD)

  • age ≥ 40 and ≤ 80 years
  • at least 10 natural teeth
  • COPD-associated hsCRP elevation (after exclusion of infection) with hsCRP > 3mg/l
  • presence of chronic periodontitis
  • at least 1 exacerbation leading to treatment with systemic glucocorticoids or antibiotics or hospitalization within the last 12 months
  • non-smoker or ex-smoker for at least the last 6 months
  • ability to understand the character and individual consequences of participation in this trial and to give written informed consent
  • provision of a written informed consent to participation in the trial prior to trial start and any trial-related procedures

Exclusion Criteria:

  • any subgingival root-planing or any kind of periodontal surgery within the last 6 months (professional tooth cleaning is allowed)
  • any antibiotics and/or systemic corticosteroid medication in the last 4 weeks before inclusion
  • any antibiotics needed as prophylaxis or as an adjunct to periodontal treatment
  • diagnostical bronchoscopy within the last 8 weeks
  • any kind of bronchoscopy and lung surgery (volume reduction, transplantation, pneumonectomy) within the last 6 months
  • concurrent participation in any interventional clinical trial (observational trials are allowed)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03279718


Contacts
Contact: Michael Kreuter, Prof. 0049-(0)6221-396-1201 kreuter@uni-heidelberg.de
Contact: Claudia Bauer-Kemeny, Dr. 0049-(0)6221-396-8217 claudia.bauer@med.uni-heidelberg.de

Locations
Germany
Clinic for Operative Dentistry, University Hospital Heidelberg Recruiting
Heidelberg, Germany, 69120
Contact: Ti-Sun Kim, Prof.    06221/56-6002    Ji-Sun.Kim@med.uni-heidelberg.de   
Medical Center for Dental and Oral Medicine, Dept. of Periodontology, Philipps-University of Marburg Recruiting
Marburg, Germany, 35039
Contact: Nicole Arweiler, Prof.    06421/5863279    arweiler@med.uni-marburg.de   
Clinic for Internal Medicine (focus Pneumology) , University Hospital Gießen und Marburg Recruiting
Marburg, Germany, 35043
Contact: Claus Vogelmeier, Prof.    06421/58-66451    vogelmei@med.uni-marburg.de   
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Michael Kreuter, Prof. Thoraxklinik, University Hospital Heidelberg

Responsible Party: Michael Kreuter, Prof. Dr. med., Heidelberg University
ClinicalTrials.gov Identifier: NCT03279718     History of Changes
Other Study ID Numbers: Expertention
First Posted: September 12, 2017    Key Record Dates
Last Update Posted: May 4, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Inflammation
Pulmonary Disease, Chronic Obstructive
Pathologic Processes
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases